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ABSTRACT
L-2-hydroxyglutarate (L-2HG) is an oncometabolite found elevated in
renal tumors. However, this molecule might have physiological roles
that extend beyond its association with cancer, as L-2HG levels are
elevated in response to hypoxia and during Drosophila larval
development. L-2HG is known to be metabolized by L-2HG
dehydrogenase (L2HGDH), and loss of L2HGDH leads to elevated
L-2HG levels. Despite L2HGDH being highly expressed in the kidney,
its role in renal metabolism has not been explored. Here, we report our
findings utilizing a novel CRISPR/Cas9 murine knockout model, with
a specific focus on the role of L2HGDH in the kidney. Histologically,
L2hgdh knockout kidneys have no demonstrable histologic
abnormalities. However, GC-MS metabolomics demonstrates
significantly reduced levels of the TCA cycle intermediate succinate
in multiple tissues. Isotope labeling studies with [U-13C] glucose
demonstrate that restoration of L2HGDH in renal cancer cells (which
lowers L-2HG) leads to enhanced incorporation of label into TCA
cycle intermediates. Subsequent biochemical studies demonstrate
that L-2HG can inhibit the TCA cycle enzyme α-ketoglutarate
dehydrogenase. Bioinformatic analysis of mRNA expression data
from renal tumors demonstrates that L2HGDH is co-expressed with
genes encoding TCA cycle enzymes as well as the gene encoding
the transcription factor PGC-1α, which is known to regulate
mitochondrial metabolism. Restoration of PGC-1α in renal tumor
cells results in increased L2HGDH expression with a concomitant
reduction in L-2HG levels. Collectively, our analyses provide new
insight into the physiological role of L2HGDH as well as mechanisms
that promote L-2HG accumulation in disease states.
KEY WORDS: L-2-hydroxyglutarate, L-2-hydroxyglutarate
dehydrogenase, TCA cycle, PPARGC1A
INTRODUCTION
Oncometabolites are small molecules that have been found elevated
in various malignancies. To date, these molecules include the
tricarboxylic acid (TCA) cycle intermediates succinate and fumarate
as well as both enantiomers of 2-hydroxyglutarate (D-2HG and
L-2HG) (Tomlinson et al., 2002; Baysal et al., 2000; Niemann and
Müller, 2000; Parsons et al., 2008; Yan et al., 2009; Green and Beer,
2010; Mardis et al., 2009). Notably, elevated oncometabolite levels
are observed with inborn errors of metabolism, such as elevated
fumarate caused by fumarase deficiency. Both forms of 2HG may
be elevated in the setting of acidurias related to loss-of-function
mutations in the D-2HG dehydrogenase (D2HGDH) or L-2HG
dehydrogenase (L2HGDH) genes (Duran et al., 1980; Kranendijk
et al., 2012; van der Knaap et al., 1999).
L-2HG has garnered recent interest as elevated levels are
observed in several other settings besides inborn errors of
metabolism. Multiple studies have demonstrated that L-2HG can
be elevated in the setting of hypoxia (Oldham et al., 2015).
Additionally, profound increases in L-2HG have been identified in
Drosophila larval development (Li et al., 2017; Li et al., 2018).
L-2HG can be created from α-ketoglutarate (α-KG) by off-target
reactions of several enzymes, including lactate dehydrogenase and
malate dehydrogenase 1 and 2 (MDH1/2) (Nadtochiy et al., 2016;
Intlekofer et al., 2017; Rzem et al., 2007). L2HGDH activity serves
to counter this off-target activity and therefore has been referred to
as an enzyme of metabolic repair. In addition, L-2HG levels are
elevated in the most common histology (clear cell) of renal cell
carcinoma (RCC) owing to loss of expression of L2HGDH.
Restoration of L2HGDH activity in several RCC models leads to
reduced L-2HG levels. Moreover, reducing L-2HG impedes tumor
growth in vivo, indicating that L-2HG promotes RCC growth. The
L2HGDH gene is located on chromosome 14q, a region commonly
deleted in RCC. As such, RCC tumors that exhibit 14q loss
demonstrate reduced L2HGDH expression (Shelar et al., 2018;
Shim and Sudarshan, 2015; Shim et al., 2014).
The cellular effects resulting from oncometabolite elevation have
been the subject of interest since their initial identification. L-2HG,
like other oncometabolites, is structurally similar to α-KG [also
referred to as 2-oxoglutarate (2-OG)]. α-KG is a metabolite of the
TCA cycle. Additionally, it serves as a co-factor for 2-OG-dependent
dioxygenases. These enzymes mediate diverse processes including
RNA, DNA and histone demethylation. As such, prior studies have
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demonstrated increased DNA/RNA/histone methylation in
oncometabolite-related tumors with corresponding gene expression
changes (Xu et al., 2011; Su et al., 2018; Shim et al., 2014). More
recently, D-2HG has been shown to inhibit enzymes that utilize α-KG
as a substrate, namely branched-chain aminotransferases (BCAT1/2)
that metabolize branched-chain amino acids (McBrayer et al., 2018).
These data suggest that oncometabolites can act via effects on gene
expression as well as direct effects on metabolism. Furthermore,
several factors can impact the effects of an oncometabolite, such as
the type of oncometabolite, the α-KG level, the amount of target
enzyme and the affinity of the oncometabolite compared with α-KG.
Thus, the effect could be tissue specific and can fluctuate based on
available nutrients.
Biallelic mutation of L2HGDH results in L-2HG aciduria, a
neurometabolic inborn error of metabolism marked by neurologic
deterioration and decreased life expectancy (Rzem et al., 2007).
Notably, it is also associated with the development of brain
tumors (Haliloglu et al., 2008). Recent studies have looked at the
effects of whole-body L2hgdh knockout (KO) mouse models.
Rzem et al. (2015) used a gene-trap cassette method that identified
that L-2HG inhibits lysine α-ketoglutarate reductase/saccharopine
dehydrogenase, leading to depletion of saccharopine and glutamine
in the brain. Additionally, Ma et al. (2017) used a piggyback
transposon gene insertion method to disrupt L2hgdh, and the
resulting mice showed extensive brain abnormalities. These studies
have provided insight into the role of L2HGDH in the brain.
Although L2HGDH is known to prevent L-2HG elevation, the
physiologic rationale for keeping L-2HG levels low remains largely
unknown. Moreover, as the prior studies focused on brain findings,
the teleologic role of this enzyme in other tissues in which it is highly
expressed remains unknown. Here, we report the creation of an
L2hgdh KO model using CRISPR/Cas9 that recapitulates the brain
abnormalities noted in prior KO models. Additionally, we
demonstrate a role for L2HGDH in mitochondrial metabolism in
the kidney, a tissuewith high basal L2HGDH expression. These data
have implications for the effects of L-2HG in physiologic as well as
pathologic states.
RESULTS
Generation of L2HGDH KO with CRISPR/Cas9
CRISPR/Cas9 genome editing was used to generate a deletion in
L2hgdh, causing a mutant allele with an 11 bp deletion. This
deletion results in a frameshift very early in exon 1, encoding the
initial 22 amino acids followed by 24 mutant amino acids and a stop
codon (Fig. 1A). We inferred this allele to result in complete loss of
function of the L2hgdh gene. This allele was successfully
transmitted through the germline, enabling us to establish a KO
line. Protein analysis of both kidney and liver tissues demonstrates
loss of L2hgdh expression relative to wild-type (WT) animals
(Fig. 1B,C). We next analyzed D-2HG and L-2HG levels via gas
chromatography–mass spectrometry (GC-MS) in liver, kidney
and gastrocnemius (striated) muscle. As heterozygous mice
demonstrated comparable L-2HG levels in all three tissues
compared with WT (+/+) mice (Fig. S2), littermate control mice
included both +/+ and +/− genotypes. Consistent with loss of
L2hgdh activity, L-2HG levels were elevated in all tissues from KO
animals compared with control animals. Moreover, kidney
demonstrated a much higher abundance of L-2HG relative to
other tissues (Fig. 1D). This result differs from a previous study,
which found similar levels of L-2HG among these tissues in KO
mice (Ma et al., 2017). Additionally, all three tissues from KO
animals demonstrated a modest increase in D-2HG, with kidney
tissue demonstrating the highest increase (Fig. 1E).
Histologic analysis of the brain and kidney
Histologic analysis of the brain was performed in 24-week-old
mice. Compared with the L2hgdh+/+mice, the brains of L2hgdh−/−
mice consistently showed spongiotic appearance and perineuronal
vacuoles, predominantly seen in the deep layers of the
cerebral cortex, consistent with prior KO models reported
(Fig. 2A). The examination of the kidney did not demonstrate
any significant differences in gross examination (Fig. 2B).
Remarkably, no significant histologic difference was noted when
comparing the kidneys from the L2hgdh+/+ and L2hgdh−/− mice
(Fig. 2C).
Fig. 1. CRISPR/Cas9 KO of L2hghd increases L-2HG
levels. (A) L2hgdh sequence of the mouse wild type (wt)
and mutant (mut) allele generated, demonstrating 11 bp
deletion with resulting frameshift (fs) and premature stop
codon. The yellow highlighted region indicates the target
protospacer adjacent motif sequence. aa, amino acids.
(B,C) Immunoblot for L2HGDH and β-actin in kidney (B) and
liver (C) tissue from L2hgdhWTand KOmice. (D,E) GC-MS
measurements of L-2HG (D) and D-2HG (E) in liver,
kidney and muscle tissues. Mice fasted for 12 h prior to
initial tissue harvest. Data are means±s.e.m.
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Decreased fertility in L2hgdh−/− male mice
We observed that L2hgdh−/− male mice had significantly reduced
fertility when bred with L2hgdh+/− females (Fig. 3A). Out of three
attempts at breeding, only one produced pups. Moreover, this litter
had only two pups. This is in stark contrast to the pairing of
L2hgdh+/− mice that produced an average of seven pups per litter.
Histologic analysis of testes and accessory sex glands did not
demonstrate any differences between WT and KO males (Fig. 3B).
Reduced succinate in tissues with high L-2HG
Prior metabolomics studies in L2hgdhKOmice focused on the brain
(Rzem et al., 2015). However, tissues including kidney, liver and
skeletal muscle also express high levels of this enzyme, with the
kidney being the highest-expressing tissue in humans (Fig. S2). We
therefore performed metabolic profiling in these tissues (in addition
to serum) that included small molecules from pathways including
glycolysis, the TCA cycle and amino acid metabolism (data
provided in Table S1). Notably, TCA cycle metabolites were not
measured in previous L2hgdh KO mice models. To minimize the
potential effects of the diet, we fasted the mice for 12 h before tissue
isolation. (n=5/group including both male and female mice).
Analysis of tissues from KO mice demonstrated significantly
decreased succinate in both kidney (P=0.0106) and muscle
(P=0.001). Additionally, this decrease in succinate was trending
toward significance in serum as well (P=0.090) (Fig. 4). There were
also several amino acids (threonine, tyrosine, and lysine) trending
toward decreased levels in KO kidneys, for which P-values were
approaching significance (Fig. 1A).
L2HGDH restoration promotes TCA cycle flux
Succinate is a known metabolite of the TCA cycle and is generated
by the enzyme succinyl-CoA ligase. As decreased succinate was
observed in multiple KO tissues, we considered the possibility of
whether elevations of L-2HG could perhaps impact the TCA cycle.
From previous studies, we found that 769-P RCC cells had reduced
L2HGDH expression with concomitant L-2HG elevation (Shelar
et al., 2018). We have previously demonstrated that the
restoration of L2HGDH expression significantly lowers L-2HG
levels. We therefore assessed the effects of L2HGDH on the
TCA cycle. 769-P cells (with or without L2HGDH) were then
cultured with fully labeled glucose [U-13C] before analysis via
liquid chromatography–mass spectrometry (LC-MS). For the
analysis, we measured total label incorporation for metabolites
of interest. We did not observe a significant difference in label
incorporation into citrate/isocitrate or α-KG (Fig. 5). However,
we observed that L2HGDH restoration led to increased label
incorporation into the TCA cycle metabolites succinate
(P=0.011) and malate (P=0.019) (Fig. 5). We also observed
that L2HGDH led to increased label incorporation into amino
acids including aspartate (P=0.017) and alanine (P=0.007).
Fig. 2. Histological analysis of L2hgdh WT (+/+) and KO (−/−) tissues.
(A) Slices of mouse cerebral cortex stained with H&E. Vacuoles (indicated
by black arrows) are noted in L2hgdh KO animals. (B) Gross images of kidneys
from WT and KO animals. (C) Slices of mouse kidney cortex stained with
H&E. Normal-appearing glomeruli and proximal tubules can be identified in
both WT and KO mice. Images displayed are at 4× and 20× magnification.
Scale bars: 200 μm.
Fig. 3. Fertility analysis of L2hgdh heterozygous (+/−) and KO male
mice. (A) Number of pups per litter generated when crossing a heterozygous
female (+/−) with either a heterozygous male (+/−) (blue) or homozygous null
(−/−) male (red). n=number of breeding pairs examined. Graph depicts two-
tailed Student’s t-test results and data are means±s.e.m. (B) Slices of
mouse testes after Bouin’s fixation and staining with H&E. Images displayed
are at 20× and 40× magnification. Scale bars: 200 μm.
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Notably, aspartate is known to be generated by transamination
of the TCA cycle intermediate oxaloacetate. No significant
difference in glucose (both labeled and unlabeled) was observed
as a function of L2HGDH (Table S2).
Impact of L-2HG on the TCA cycle
As noted, α-KG-dependent dioxygenases are known to catalyze the
demethylation of DNA, RNA and histones. Therefore, oncometabolites
could impact gene expression via effects on transcription and/or protein
translation. Prior analyses demonstrated reduced expression of TCA
cycle enzyme expression in RCC specimens (Cancer Genome Atlas
Research Network, 2013; Wettersten, 2020). We therefore considered
whether L-2HG suppressed the expression of TCA cycle enzymes,
thereby leading to reduced TCA cycle flux. We restored L2HGDH
(bothWT and A241Gmutant) in 786O and 769-P RCC cells (Fig. S3).
As expected, WT L2HGDH lowered L-2HG, whereas the mutant
did not affect L-2HG levels (Fig. S4A,B). In both cell lines,
modulation of L-2HG levels had no impact on TCA cycle enzyme
mRNA or protein expression (Fig. S4C-E).
We, therefore, considered alternative mechanisms by which
L-2HG could impact the TCA cycle. Recent studies demonstrate
that D-2HG can inhibit enzymes that utilize α-KG as a substrate.
Within the TCA cycle, α-KG dehydrogenase (α-KGDH) converts
α-KG to succinyl-CoA, which is subsequently converted to
succinate. In turn, succinate is converted to other TCA cycle
intermediates (e.g. malate) as well as metabolites derived from TCA
cycle intermediates (e.g. aspartate). Based on our findings related to
the TCA cycle, we hypothesized that L-2HG could directly inhibit
the enzymatic activity of α-KGDH (Fig. 6A). Using an in vitro
biochemical assay, we observed that L-2HG led to a dose-dependent
inhibition of α-KGDH enzymatic activity (Fig. 6B).
These biochemical data led us to surmise that the teleological role
for L2HGDH in the kidney is to keep L-2HG levels low such that
TCA cycle flux is maintained. To further support this role for
L2HGDH, we examined co-regulated genes within The Cancer
Genome Atlas (TCGA) data set on clear cell RCC (KIRC) using the
Genomic Regression Analysis of Coordinated Expression (GRACE)
tool (Cai et al., 2017) (Table S3). This algorithm performs co-
expression analyses while accounting for the potential effects of copy
number alterations, which commonly occur in cancers. This is
particularly relevant as copy number loss of L2HGDH is found in
42.5% of clear cell RCC patients based on TCGA analysis (data not
shown). Using a Spearman Rho rank threshold of 0.3 (at least
moderate association), we performed a pathway analysis of positivity
associated genes with the Enrichr tool (https://amp.pharm.mssm.edu/
Enrichr/). This analysis demonstrated that L2HGDH is coordinately
expressed with genes involved in pathways including branched-chain
amino acid degradation, peroxisomes, fatty acid metabolism and the
TCA cycle (Fig. 6C). TCA cycle genes that positively correlate with
L2HGDH are shown in Fig. 6D. Utilizing the Spearman Rank Rho
for rank order of genes from the GRACE analysis, we performed
pathway analysis utilizing all genes with the Webgestalt tool. Fig. 6E
displays the TCA cycle enrichment plot from the analysis. Both the
false discovery rate (FDR) and P-value were <0.001. These
bioinformatics analyses provide further evidence on the role of
L2HGDH in promoting TCA cycle metabolism, which corresponds
with our biochemical studies.
Analternativemechanism for reduced L2HGDHand elevated
L-2HG
L-2HG build-up in RCC is caused by loss of L2HGDH expression.
Our laboratory has previously reported that 14q loss, the chromosomal
location for the L2HGDH gene, is significantly associated with
decreased L2HGDH mRNA. Notably, heterozygous loss of L2hgdh
in mice (L2hgdh+/−) resulted in reduced L2HGDH protein (Fig. 7A)
but was not sufficient to significantly increase 2HG levels in the
kidney (Fig. 7B). Only homozygous loss of L2hgdh led to increased
2HG in the kidney. These data suggest that although gene copy loss
can reduce L2HGDH expression, this mechanism alone does not
result in raised L-2HG, and that alternative mechanisms exist that
reduce L2HGDH in RCC to the point that L-2HG becomes elevated.
As further supportive evidence, we analyzed L2HGDH mRNA
expression and gene copy number in normal kidney and RCC
specimens. RCC specimens were separated into high and low L-
2HG tumors based on whether levels were within two standard
deviations of normal kidney median. A log-log plot of linear
regression analysis identified a negative correlation with a R2 of
Fig. 4. Metabolite profiling of WT and KO tissues. GC-MS metabolite
profiling of tissues and serum fromWT and KOmice. Mice were fasted for 12 h
prior to sample harvest and metabolite extraction. Values are normalized to
L2hgdh WT metabolite amount. n=5 mice for each group. Both groups
contain both male and female mice. Graphs depict two-tailed unpaired
Student’s t-test results and data are means±s.e.m.
Fig. 5. Metabolite flux analysis of 769-P RCC cells with or without
L2HGDH, incubated with [U-13C] glucose. 769-P RCC cells were stably
transducedwith control vector or L2HGDH. Cells were then treatedwith [U-13C]
glucose for 24 h followed by metabolite extraction and LC-MS profiling. Values
represent total 13C label incorporation into the indicated metabolite. Graph
depicts two-tailed unpaired Student’s t-test results and data are means±s.e.m.
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0.1410 (Fig. 7C). Next, we analyzed high L-2HG tumors for
L2HGDH copy loss. Although eight of 13 high-L-2HG tumors
demonstrated L2HGDH copy loss, we noted five tumors with raised
L-2HGwithout evidence of copy loss (Fig. 7D). As a control for our
copy number analysis, we examined HIF1A, which is also located
on 14q. Of the eight high-L-2HG tumors that demonstrated
L2HGDH copy loss (monoallelic loss), six tumors also
demonstrated HIF1A copy loss (Fig. 7E). Correspondingly, of the
five high-L-2HG tumors without L2HGDH copy loss, four tumors
did not demonstrate HIF1A loss. Collectively, these data further
support our findings that alternative mechanisms can promote loss
of L2HGDH expression with ensuing elevated L-2HG in RCC.
Based on the combined analysis of our KO model and
biospecimens, we sought to identify alternative mechanisms for
reduced L2HGDH/elevated L-2HG in RCC. Utilizing our
information from pathway analysis of genes co-regulated with
L2HGDH, we attempted to identify potential transcription factors
that are known to regulate mitochondrial metabolic pathways and
that are reduced in RCC. One such transcription factor identified
was the gene PPARGC1A, which encodes peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α). Our
laboratory recently reported on reduced PGC-1α in RCC tissues
and multiple RCC lines with reduced expression (Nam et al., 2020).
Analysis of TCGA data on clear cell RCC demonstrates that
PPARGC1A and L2HGDH mRNA are positively correlated
(Fig. 8A). Restoration of PGC-1α expression via adenovirus
increased the mRNA expression of L2HGDH in multiple RCC
lines examined (Fig. 8B). Furthermore, stable expression of PGC-
1α via lentiviral transduction in RXF-393 cells increased L2HGDH
protein and significantly reduced L-2HG levels (Fig. 8C-D).
Additionally, knockdown of PPARGC1A utilizing small
interfering RNA (siRNA) decreased L2HGDH protein in both
HK2 renal epithelial cells and HEK293T embryonic kidney cells
(Fig. 8E; Fig. S5). PPARGC1A knockdown was confirmed by
quantitative PCR (qPCR) (Fig. 8F). Collectively, these data
demonstrate a role for PGC-1α in regulating L2HGDH expression
and L-2HG levels.
DISCUSSION
L-2HG can have widespread effects on a cell. L-2HG has been
shown to competitively inhibit enzymes that utilize α-KG as a co-
factor with effects on DNA and histone methylation. Finding the
models to reflect the most impactful effects of L-2HG accurately is
essential to better understand its role in cancer, hypoxia and
development. There is an abundance of different techniques that can
be used for in vivo gene-edited mouse models. Recent studies have
shifted to CRISPR/Cas9 for both its ease to generate models and its
specificity (Weber and Rad, 2019). We thus compared our new
model to previous models and found similar characteristics. All
models showed increased L-2HG in all tissues tested and abnormal
pathology in brain tissue (Rzem et al., 2015;Ma et al., 2017). Unlike
previous models, our L2hgdh KO mouse model demonstrated more
pronounced L-2HG elevation in the kidney compared with the liver
and muscle. Moreover, KO males showed significantly reduced
fertility (Fig. 3). Testes are also known to express L2HGDH.
Notably, rodent testes express a variant of LDH-C, which can
produce high levels of L-2HG (Teng et al., 2016).
We used this model to examine the biochemical implications of
raised L-2HG in the kidney, the tissue with the highest expression of
L2HGDH in humans (Fig. S2). We used a metabolomic approach to
study the effects of L-2HG. Our GC-MS analysis of the kidney and
muscle tissues demonstrated a significant decrease in succinate
Fig. 6. The L-2HG/L2HGDH axis and the TCA cycle.
(A) Schematic of the proposed effects of L-2HG on the TCA
cycle based on flux analysis. (B) Effects of increasing L-2HG
levels on α-KGDH enzymatic activity in vitro. α-KGDH
enzymatic product formation was measured based on optical
density (OD) at 450 nm. (C) KEGG (https://www.genome.jp/
kegg/) pathway analysis of L2HGDH positively correlated
genes in clear cell RCC with Spearman Rank >0.3 (moderate
association). Co-expression analysis performed by GRACE
(https://grace.biohpc.swmed.edu/). Pathway analysis
performed by Enrichr (https://amp.pharm.mssm.edu/Enrichr/).
Data are from the TCGA Kidney Renal Clear Cell Carcinoma
(KIRC) data set. (D) TCA cycle genes positively correlatedwith
L2HGDH from the KEGG TCA cycle pathway in C.
(E) Enrichment plot of KEGG TCA cycle using all genes from
KIRC L2HGDH GRACE analysis. Analysis was performed by
Webgestalt (http://www.webgestalt.org/) utilizing Spearman
Rank Rho for rank order.
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levels compared with control mice (P=0.01 and P=0.001,
respectively), leading us to hypothesize a link between L-2HG
and the TCA cycle. Interestingly, KO liver did not show a significant
difference in succinate levels. One possible explanation is that the
degree of L-2HG elevation in KO liver was less than that observed in
kidney and muscle (Fig. 1D). Alternatively, these data could
indicate that the effects of L-2HG are tissue dependent.
The link between L-2HG and the TCA cycle is particularly
intriguing as RCC tumors are known to demonstrate reduced
expression of TCA cycle enzymes (Cancer Genome Atlas
Research Network, 2013). Correspondingly, isotope labeling
studies with [U-13C] glucose in patients (Courtney et al., 2018)
provided a reference for interpretation of our analyses. The authors
demonstrate reduced TCA cycle labeling in RCC relative to normal
kidney. Reintroduction of L2HGDH to RCC cells led to increased
13C labeling of TCA cycle metabolites, including succinate and
malate, as well as metabolites derived from the TCA cycle such as
aspartate. Interestingly, there were no significant differences in the
labeling of TCA metabolites earlier in the cycle (citrate/isocitrate and
α-KG). Similarly, reduced labeling in TCA cycle metabolites
succinate, fumarate and malate, but not in metabolites earlier in the
cycle, such as citrate, was observed (Courtney et al., 2018). These
data led us to focus on α-KGDH. As further evidence for a link
between L-2HG and α-KGDH, bacterial species of Marinomonas
often demonstrate the clustering of αKGDH subunit genes and ygaF,
the gene encoding the bacterial equivalent of L2HGDH (Seaver et al.,
2012). These data reinforce the role of L2HGDH as an enzyme of
metabolite repair by keeping L-2HG levels ‘in check’, such that
α-KGDH activity is maintained. One caveat to our studies is that
alternative carbon sources can contribute to TCA cycle anaplerosis.
This is particularly relevant as glucose entry into the TCA cycle is
impaired in RCC due to HIF1A-mediated inhibition of pyruvate
dehydrogenase (Papandreou et al., 2006; Kim et al., 2006). For
example, glutamine can be metabolized to α-KG. Hence, raised
L-2HG could impact the anaplerotic role of these alternative carbon
sources.
Our data demonstrate that L-2HG promotes TCA cycle
dysfunction and provide new insight into the mechanisms that lead
to a classic Warburg phenotype in RCC. Despite these data, the true
biological significance of L2HGDH remains poorly characterized.
Nevertheless, they may provide new opportunities for intervention.
The TCA cycle represents a major bioenergetic hub with cataplerotic
activities that are known to have biosynthetic functions. Hence, raised
L-2HG may create potential metabolic liabilities that could be used
for treating tumors. Alternatively, potential deficiencies resulting
from these metabolic liabilities could be treated with supplementation
in patients with 2HG acidurias.
Our study has provided new insight into the regulation of
L2HGDH based on our finding that biallelic loss of L2hgdh was
required to raise renal L-2HG levels. These data indicate that single-
copy loss of L2HGDH alone is not sufficient to lower L2HGDH
expression to the point that L-2HG levels are increased in kidney
tumors. As further evidence, we identified several renal tumors with
low L2HGDH expression/elevated L-2HG without L2HGDH copy
loss. These data allude to the importance of L-2HG in RCC in that
reduced L2HGDH expression is not merely a bystander effect
associated with copy loss, but instead suggest that there is a
concerted effort to silence this gene in RCC.
Our results also provide new insight into the role of PGC-1α in
mitochondrial metabolism. PGC-1α has been shown to promote
oxidative metabolism via transcriptional regulation of genes
encoding oxidative phosphorylation subunits and TCA cycle
enzymes (LaGory et al., 2015; Calvo et al., 2008; Koves et al.,
2005; Bhalla et al., 2011). Our data demonstrate that PGC-1α also
promotes TCA cycle metabolism via L2HGDH transcription, which
lowers L-2HG levels. One caveat of our experiments is that all cell
lines examined have a heterozygous loss of L2HGDH (Fig. S1). As
a result, the effects of PGC-1α on L2HGDH transcription might be
Fig. 7. Alternative mechanisms contribute to decreased
L2HGDHmRNA in kidney cancer. (A) Immunoblot of L2HGDH
in kidneys from L2hgdh+/+, L2hgdh+/− and L2hgdh−/− mice.
(B) Renal 2HG (normalized) from mice with the indicated
genotype. (C) L2HGDH mRNA (x-axis) and L-2HG metabolite
levels (y-axis) in RCC tumors and normal kidney (black). RCC
tumor samples were designated as either low L-2HG (blue) or
high L-2HG (red). Low L-2HG designation is based onmetabolite
level within two standard deviations away from normal kidney
median L-2HG levels. Correlation line created in GraphPad
Prism 8 using log-log line non-linear fit. (D,E) Copy number
analysis by qPCR for L2HGDH (D) and HIF1A (E) in normal
kidney and high L-2HG renal tumors. Both genes are located on
14q. Red values depict tumors with copy loss for L2HGDH.
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dampened. Although L-2HG does not have effects on the
expression of TCA cycle enzymes in RCC, it can affect TCA
cycle metabolism. As a result of low L-2HG levels, α-KGDH
activity is maintained, thereby promoting TCA cycle flux. These
data, therefore, indicate that the teleological role for L2HGDH, at
least in the kidney, is to promote mitochondrial metabolism, which
is in line with our biochemical findings. Our findings are consistent
with previous work demonstrating that high D-2HG levels can
lower α-KGDH activity in cardiac muscle tissue. However, the
direct inhibitory role of D-2HG on α-KGDH enzymatic activity was
not examined (Karlstaedt et al., 2016). These data are in line with
prior studies that have demonstrated that both enantiomers of 2HG
can inhibit enzymes that utilize α-KG as a co-factor or substrate. Our
study focused on L-2HG because D-2HG is not significantly
elevated in RCC. Further studies on the effects of D-2HG on TCA
cycle metabolism in IDH mutant tumors would be of interest.
In summary, this paper highlights the creation and analysis of a
novel L2hgdh KO mouse model in concert with human RCC tissue
analysis to study the metabolite L-2HG. We demonstrate a role for
L2HGDH in promoting mitochondrial metabolism in the kidney.
These data provide new insights into the pathophysiological




L2HGDH (WT) and L2HGDH mutant (A241G) complementary DNA
(cDNA) have been previously described (Shelar et al., 2018). To generate
stable cell lines, lentiviral plasmids were transfected with packaging vectors
into HEK293T cells using the calcium chloride method. Supernatants from
transfected HEK293T cells were collected after 72 h, filtered and applied to
cells. Viral transduced cells were selected in culture medium containing
puromycin. All transduced cells represent polyclonal populations.
Adenovirus
PPARGC1A (encoding PGC-1α) and GFP control adenovirus were
purchased from Vector Biolabs. Cells were analyzed 48-72 h after
transduction. A multiplicity of infection (MOI) of 100 was used for all
experiments.
siRNA studies
Cells were seeded on six-well plates for 48 h. Cells were then transfected
with 50 nM of a negative control siRNA or siRNA against PGC-1α using
Lipofectamine® RNAiMAX regent (Invitrogen) for 48 h. Additional
methods were as described previously (Nam et al., 2020).
Generation of L2HGDH KO mice
In order to create loss-of-function alleles of the mouse L2hgdh
gene (ENSMUSG00000020988), CRISPR targets were chosen in the
coding region of exon 1 (ENSMUSE00000113742; Transcript ID
ENSMUST00000021370.9) using the Massachusetts Institute of
Technology CRISPR design tool (https://zlab.bio/guide-design-resources).
Two guide sequences with high scores that indicated a low number of off-
target sites were chosen: C1, AGACACCGCCTACGTAGCGC(AGG); and
C2, ACGCCGGTCCACTTGCGCGG(AGG). Guide RNA molecules were
generated using the method described by Hwang et al. (2013). Cas9 mRNA
was prepared by in vitro transcription using a linearized pCS2-nCas9n
plasmid template (Jao et al., 2013).
Genotyping G0/founders and F1 animals to identify mutant
alleles
Genotyping by PCR-heteroduplex mobility assay (HMA) was employed to
identify indels in the G0/founder animals (Challa et al., 2016), using the
following primers: forward 5′-CCTTAGAGTCCGTTCAGGTTG-3′;
reverse 5′-GGACACAGACAGGTTCAGTTG-3′, which amplified a
271 bp fragment. The PCR amplicons were cloned and sequenced using
the Sanger method to obtain the mutant allele information.
Pathology
Reproductive tissues were fixed in Bouin’s solution before being processed.
All other tissues were formalin fixed before processing by the University of
Alabama at Birmingham (UAB) Comparative Pathology Laboratory. Fixed
tissue was placed onto slides and stained with Hematoxylin and Eosin
(H&E) for analysis.
Mouse tissue GC-MS
Mice were fasted for 12 h before tissue isolation. Tissues were briefly
washed in ice-cold Dulbecco’s PBS, followed by rapid freezing in liquid
nitrogen. Metabolite extraction and derivatization were conducted using a
modified version of previously described protocols (Chan et al., 2011;
Gibson et al., 1993; Pasikanti et al., 2008). Briefly, samples were added to
pre-tared 2 ml screw cap tubes containing 1.4 mm ceramic beads, massed,
and 800 µl of −20°C methanol with 2 µg/ml of both d4-succinic acid
and disodium (R,S)-[2,3,3-2H3]-2-hydroxyglutarate ([2H3]-2HG) (C/D/N
Isotopes, Canada) was added to the tubes. Samples were homogenized in an
Omni Beadruptor 24 for 30 s at 6.45 m/s, returned to a −20°C benchtop
enzyme cooler, and incubated at −20°C for 1 h. Samples were then
centrifuged at ∼20,000 g in a refrigerated centrifuge for 5 min to pellet
insoluble debris. The supernatant was removed, evenly split between two
tubes and dried in a vacuum centrifuge. One tube was derivatized using a
previously described method to quantify D-2HG and L-2HG levels. The
Fig. 8. PGC-1α regulates L2HGDH expression. (A) TCGA KIRC (clear cell
RCC) correlation plot comparing RNA-Seq by Expectation Maximization
(RSEM) RNAvalues for PPARGC1A and L2HGDH using cBIO analysis portal
(http://www.cbioportal.org/). (B) L2HGDH mRNA expression was assessed in
RCC lines following adenoviral delivery of PGC-1α relative to control
adenovirus. (C) Immunoblot analysis for L2HGDH following stable lentiviral
(LV) expression of PGC-1α in RXF-393 RCC cells. In the PGC-1α immunoblot,
the lower band represents the non-specific band. (D) L-2HG levels in RXF-393
cells with or without PGC-1α. (E) Immunoblot for L2HGDH in HK2 renal
epithelial cells following transfection with the indicated siRNA. (E) RT-qPCR for
PPARGC1A following treatment with the indicated siRNA in HK2 cells. Graphs
depict two-tailed unpaired Student’s t-test results and data are means±s.e.m.
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second tube was derivatized using methoxylamine hydrochloride (MOX)
and N-methyl-N-trimethylsilyltrifluoracetamide (MSTFA) to measure the
relative abundance of organic acids, amino acids and glycolytic
intermediates. Derivatized samples were injected into an Agilent 7890B/
7250 GC-QTOF instrument (1:10 split ratio) equipped with a Phenomex
ZB5-5 MSi column using a Gerstel MPS autosampler using previously
described methods (Li and Tennessen, 2018). Data were analyzed using
MassHunter Qualitative Analysis and MassHunter Quantitative Analysis.
Power analysis based on preliminary data was calculated with mu1: 1, mu2:
1.5, sigma of 0.25 alpha: 0.05, and power: 0.8, demonstrating a minimal
need for four mice. We used n=5 mice in the analysis. Both groups included
both male and female mice.
Cell culture
Renal cell lines were acquired from American Type Culture Collection
(ATCC) except for RXF-393 [obtained from the National Cancer Institute
(NCI)]. Cells acquired from ATCC and the NCI were characterized via short
tandem repeat (STR) profiling. As cells were passaged for less than
3 months after resuscitation and were periodically screened forMycoplasma
using a PCR-based assay, no further authentication was performed.
HEK293T and Caki-1 cells were maintained in Dulbecco’s modified
Eagle medium containing 10% fetal bovine serum (FBS) and penicillin/
streptomycin. RXF-393, 769-P and 786O cells were maintained in RPMI
containing 10% FBS and penicillin/streptomycin. Phenotype/genotype
information for cell lines used including L2HGDH expression, VHL status
and copy number status is provided in Fig. S1.
Bioinformatics/TCGA analysis
Co-expression analysis of TCGA data on clear cell renal cancer (KIRC) was
performed using the GRACE analysis tool (https://grace.biohpc.swmed.edu/)
(Cai et al., 2017) as well as the cBIO analysis portal (www.cbioportal.org)
(Gao et al., 2013; Cerami et al., 2012). Kyoto Encyclopedia of Genes and
Genomes (KEGG) (https://www.genome.jp/kegg/) (Kanehisa and Goto,
2000; Kanehisa et al., 2019; Kanehisa, 2019) was used for pathwaymapping.
Pathway analysis was performed by Enrichr (Chen et al., 2013; Kuleshov
et al., 2016) (https://amp.pharm.mssm.edu/Enrichr/). Enrichment analysis
was performed by Webgestalt (http://www.webgestalt.org/) (Liao et al.,
2019; Wang et al., 2017; Wang et al., 2013; Zhang et al., 2005).
α-KGDH assay
The enzymatic assay was obtained from BioVision. For cell-independent
experiments, α-KGDH enzyme and necessary co-enzymes were incubated
with increasing concentrations of L-2HG. L-2HG was synthesized as
previously described (Shim et al., 2014). Optical density readings at 450 nm
were taken every 5 min over 70 min.
Tumor copy number analysis
Clear cell RCCs and normal tissues were acquired from the Cooperative
Human Tissue Network. DNA was isolated from tissues using a Qiagen
DNeasy Blood and Tissue Kit. Gene copy number was determined using
commercially available TaqMan Copy Number assays with fluorescein
amidite dye-labeled probes: Hs02530250_cn (HIF1A), and
Hs07069935_cn (L2HGDH) (Thermo Fisher Scientific). The TERT
TaqMan copy number reference with a VIC dye-labeled probe (4403316)
was used as the two-copy reference (Thermo Fisher Scientific). PCR
reactions were performed in triplicate in a 20 μl reaction containing 80 ng
DNA, 1× TaqMan Universal PCR Master Mix (Thermo Fisher Scientific),
1× gene-specific Copy Number Assay and 1× Copy Number Reference
Assay. The reactions were cycled at 95°C for 10 min, followed by 40 cycles
of 95°C for 15 s and 60°C for 1 min in a Bio-Rad CFX96 Touch Real-Time
PCR system. Cq (Ct) values were determined using the CFX Manager
software (Bio-Rad). Gene copy numbers for the test samples were
determined using the 2−ΔΔCq method with a two-copy calibrator.
RNA and protein analysis
Total RNA from cultured cells was extracted using Trizol reagent (Invitrogen).
cDNA was synthesized using a High-Capacity cDNA Reverse Transcription
Kit (Thermo Fisher Scientific). Real-time qPCR was performed using the
following TaqMan gene expression assays (Thermo Fisher Scientific):
L2HGDH (Hs00227575), PPARGC1A (Hs00173304_m1), MDH1
(Hs00936497_g1), MDH2 (Hs00938918_m1), ACO2 (Hs00426616_g1)
and OGDH (Hs01081865_m1). HPRT1 (Hs02800695_m1) and RPLPO
(hs99999902_m1) probes were used as an internal control, and the ΔΔCt
methodwas used to calculate relativemRNA levels. For immunoblotting, anti-
α-L2HGDH (GeneTex, GTX32695, 1:2000; and Novus, NBP2-85197,
1:1000), anti-PGC-1α (Abcam, ab54481, 1:1000) anti-α-MDH2 (Abcam,
ab96193, 1:3000), anti-MDH1 (Novus, NBP1-895151, 1:3000) and anti-β-
actin (Abcam, ab20272, 1:3000) were used as per the manufacturers’
instructions.
2HG enantiomer analysis (i.e. D-2HG and L-2HG quantification)
Samples were analyzed as previously described (Rakheja et al., 2011).
Enantiomer analysis was performed following derivatization with diacetyl-
L-tartaric acid followed by liquid chromatography–tandem mass
spectrometry (LC-MS/MS) analysis and normalized to protein levels.
Total 2HG measurements
Total 2HG (D-2HG+L-2HG) measurement of samples from renal tissues
was performed as previously described (Shim et al., 2014). Briefly, tissues
were washed in PBS, followed by extractions with 10% cold trichloroacetic
acid (TCA). Following centrifugation and removal of the precipitate, TCA in
the supernatant was removed by vortexing with four volumes of 1,1,2-
trichlorotrifluoroethane-trioctylamine (Sigma-Aldrich) mixture. The
aqueous layer was collected and analyzed by ion chromatography coupled
with negative electrospray mass spectrometry (Dionex).
LC-MS isotope labeling analysis
Cells were plated with RPMI with 10% dialyzed FBS, and penicillin/
streptomycin. After 24 h, [U-13C]-glucose was added to the medium for
24 h. Cells were then washed with ice-cold 0.9% NaCl in molecular-grade
water. Cells were lysed in 80% LC-MS methanol and scraped into 1.5 cm3
conical vials. Cells were then placed in the freezer at −80°C and further
processed on dry ice. Cells were spun at full speed for 20 min at 4°C. The
supernatant was split between two samples and dry vacuumed at room
temperature until no liquid remained. The dry pellets were reconstituted into
30 ml sample solvent (water:methanol:acetonitrile, 2:1:1, v/v) and 3 ml was
further analyzed by LC-MS. The liquid chromatography method was as
described previously (Liu et al., 2015, 2014), except that mobile phase A
was replaced with water containing 5 mM ammonium acetate (pH 6.8).
The Q Exactive Plus mass spectrometer is equipped with a heated
electrospray ionization probe with related parameters set as below: heater
temperature, 120°C; sheath gas, 30; auxiliary gas, 10; sweep gas, 3; spray
voltage, 3.0 kV for the positive mode and 2.5 kV for the negative mode;
capillary temperature, 320°C; S-lens, 55; scan range (m/z), 70-900 for
positive mode (1.31-12.5 min) and negative mode (1.31-6.6 min) and 100-
1000 for negative mode (6.61-12.5 min); resolution: 70,000; automated
gain control, 3×106 ions. Customized mass calibration was performed
before data acquisition. LC-MS peak extraction and integration were
performed using commercially available software Sieve 2.2 (Thermo
Fisher Scientific). The peak area was used to represent the relative
abundance of each metabolite in different samples. The missing values
were handled as described previously (Liu et al., 2014).
Statistical analysis
Statistical analyses were carried out using GraphPad Prism 6 software.
Comparisons between groups for statistical significance were performed
with two-tailed unpaired Student’s t-tests with P<0.05 considered
significant unless otherwise specified.
Study approval
All mouse experiments were performed following the Guide for the Care
and Use of Laboratory Animals published by the National Institutes of
Health, and experimental protocols were approved and conducted according
to the UAB Institutional Animal Care and Use Committee.
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